CDK4/6 inhibitors in HER2-positive breast cancer.
Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, showing very promising results in the preclinical and clinical settings. The first selective inhibitors of CDK4/6 received breakthrough status and FDA approval in combination with letrozole (February 2015) and fulvestrant (February 2016) as first-line therapy in ER-positive advanced and metastatic BC. Considering the success of this family of compounds in hormone-positive BC, new possible applications are being investigated in other molecular subtypes. This review summarizes the latest findings on the use of CDK4/6 inhibitors in HER2 positive BC.
Peter MacCallum Cancer Centre, Radiation Oncology Department, Moorabbin Campus, East Bentleigh Victoria 3165, Australia. Electronic address: Paola.Corona@petermac.org.
Silvia Paola
SP
Corona
Universita degli Studi di Parma, Department of Clinical and Experimental Medicine, Experimental Oncology Unit, Via Gramsci, 14, Parma, Italy.
Andrea
A
Ravelli
Universita degli Studi di Parma, Department of Clinical and Experimental Medicine, Experimental Oncology Unit, Via Gramsci, 14, Parma, Italy.
Daniele
D
Cretella
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy.
Maria Rosa
MR
Cappelletti
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy.
Laura
L
Zanotti
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy.
Martina
M
Dester
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy.
Angela
A
Gobbi
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy.
Pier Giorgio
PG
Petronini
Azienda Ospedaliera di Cremona, U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, Cremona, Italy; Universita degli Studi di Trieste, Department of Medical, Surgery and Health Sciences, Trieste, Italy.
Daniele
D
Generali
D001943:Breast Neoplasms / Q000188:drug therapy*; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077267:Fulvestrant; D006801:Humans; D000077289:Letrozole; D058990:Molecular Targeted Therapy / Q000379:methods*; D009570:Nitriles / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D014230:Triazoles / Q000627:therapeutic use
D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D004958:Estradiol; D000077267:Fulvestrant; D000077289:Letrozole; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D014230:Triazoles; C508053:ERBB2 protein, human; C495900:CDK4 protein, human; C495911:CDK6 protein, human
Abemaciclib; Advanced breast cancer; Breast cancer; Cyclin-dependent kinases (CDK); HER2 positive BC; Palbociclib; Ribociclib